)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Ipca Laboratories
Ipca Laboratories (IPCALAB) investor relations material
Ipca Laboratories Q2 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 26/27 earnings summary5 Nov, 2026
Executive summary
Q2 FY27 standalone revenue from operations rose 17% YoY to ₹2,255.61 crore; consolidated revenue increased 14% to ₹2,909.94 crore.
H1 FY27 standalone and consolidated net profit after tax increased 34% to ₹760.58 crore and 51% to ₹777.02 crore, respectively.
Q2 consolidated EBITDA margin rose to 22.97% from 21.68%; standalone margin increased to 26.61% from 25.46%, excluding forex gains/losses, other income and exceptional items.
Financial highlights
Q2 standalone net profit after tax was ₹387.29 crore, up 27% YoY; consolidated net profit attributable to owners was ₹375.13 crore, up 33%.
H1 revenue from operations grew 19% standalone to ₹4,374.85 crore and 17% consolidated to ₹5,698.04 crore.
Q2 standalone EBITDA before forex, other income and exceptional items rose 22% to ₹600.22 crore; consolidated EBITDA on the same basis increased 21% to ₹668.27 crore.
H1 standalone EBITDA on the same basis rose 27% to ₹1,157.04 crore; consolidated EBITDA increased 33% to ₹1,306.21 crore.
Q2 EPS after exceptional items was ₹15.27 standalone and ₹14.79 consolidated; H1 EPS was ₹29.98 and ₹30.63, respectively.
Outlook and guidance
FY27 growth guidance remains 14%-16% and consolidated EBITDA margin guidance 22%-23%, with no revision; consolidated margin is expected to improve 1%-1.25% annually and standalone margin ~1.5% annually.
Institutional sales may reach ₹325-340 crore this year, above the earlier ₹300 crore guidance; management cautioned growth may ease next year.
Pain portfolio growth of 14%-15% is expected to continue over the next 3-4 years; umbrella brand sales have exceeded ₹1,500 crore.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Ipca Laboratories
- FY24 revenue and profit grew, while Q4 earnings absorbed substantial exceptional charges.IPCALAB
Q4 23/24 - Net profit up 80% and EBITDA margin at 22.88%, with FY27 growth guidance raised to 14%-16%.IPCALABQ1 26/27
- Strong FY26 revenue and profit growth, margin expansion, and positive FY27 outlook.IPCALABQ4 25/26
- Q3 FY26 saw strong profit and margin growth, led by chronic therapies and exports.IPCALABQ3 25/26
- EBITDA margins and profits rose, led by domestic and API growth, with export recovery expected.IPCALABQ2 25/26
- Q2 FY25 net profit up 58%, revenue up 15%, margins improved; interim dividend declared.IPCALABQ2 24/25
- Strong domestic growth and margin outperformance offset export decline and EU fine provision.IPCALABQ1 24/25
- Net profit before exceptionals jumped 56% on 15% income growth and margin expansion.IPCALABQ4 24/25
- Q3 FY25 net profit rose 38% with record margins and strong domestic and chronic segment growth.IPCALABQ3 24/25
Next Ipca Laboratories earnings date
Q3 26/274 Feb, 2027
Ipca Laboratories
Next Ipca Laboratories earnings date
Q3 26/274 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Ipca Laboratories Limited is an India-based pharmaceutical company engaged in the manufacturing and marketing of active pharmaceutical ingredients and finished dosage forms. The company’s products cover therapeutic segments such as pain management, cardiovascular, anti-malarial, anti-infective, and dermatology. Ipca serves domestic and international markets, supplying to both branded and generic sectors, and also operates in the institutional supply segment. The company is headquartered in Mumbai, India, and its shares are listed on the BSE.